Pdt Partners, LLC Apellis Pharmaceuticals, Inc. Transaction History

Pdt Partners, LLC

$1.01 Billion
Q1 2024

A detailed history of Pdt Partners, LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 56,521 shares of APLS stock, worth $2.17 Million. This represents 0.33% of its overall portfolio holdings.

Number of Shares

56,521

Previous 51,951 8.8%

Holding current value

$2.17 Million

Previous $3.11 Million 6.85%

% of portfolio

0.33%

Previous 0.35%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$55.39 - $72.47 $253,132 - $331,187	4,570 Added 8.8%	56,521 $3.32 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $504,175 - $879,931	-13,575 Reduced 20.72%	51,951 $3.11 Million
Q3 2023 Nov 14, 2023	BUY	$23.65 - $89.22 $955,838 - $3.61 Million	40,416 Added 160.96%	65,526 $2.49 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $635,370 - $773,166	8,286 Added 49.25%	25,110 $2.29 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $783,830 - $1.13 Million	16,824 New	16,824 $1.11 Million

Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $1.05 Million - $1.63 Million	-23,390 Reduced 38.41%	37,504 $2.56 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $2.14 Million - $3.61 Million	60,894 New	60,894 $2.75 Million
Q1 2020 May 15, 2020	SELL	$17.91 - $44.33 $1.43 Million - $3.55 Million	-80,017 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$22.1 - $30.8 $716,371 - $998,382	32,415 Added 68.1%	80,017 $2.45 Million
Q3 2019 Nov 14, 2019	BUY	$24.09 - $32.18 $257,329 - $343,746	10,682 Added 28.93%	47,602 $1.15 Million
Q2 2019 Aug 14, 2019	BUY	$18.0 - $25.34 $153,360 - $215,896	8,520 Added 30.0%	36,920 $936,000
Q1 2019 May 15, 2019	BUY	$12.81 - $19.82 $363,804 - $562,888	28,400 New	28,400 $554,000

Others Institutions Holding APLS

# of Institutions

337

Shares Held

111M

Call Options Held

1.26M

Put Options Held

1.14M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $4.21B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account